Kurt T. Mulville is a Partner in the firm’s Intellectual Property Practice Group with over 3 1/2 decades history and broad expertise in startup companies in the Medical and Life Sciences from transgenics, to pharmaceuticals, and medical instruments and devices, particularly for minimally invasive cardiac surgery and drug:device combinations for aerosol drug delivery. Kurt has performed a key role in developing, defending, securing funding, and enforcing IP rights in these and other highly competitive industries and technologies.
From 1990 to 2012, he practiced law with the preeminent Los Angeles firm Lyon & Lyon and was a partner there from 1997-2012, principally litigating patent disputes in genetic engineering, pharmaceuticals, and medical devices. From 2002 to 2013, he was a partner at Orrick Herington & Sutcliffe continuing his practice in strategic technology transfer, patent and IP litigation, including litigation in state court trade secret matters, federal district court patent cases, Federal Circuit appeals, ITC proceedings, and ex parte and inter partes matters at the USPTO. He is also frequently retained to render opinions and perform intellectual property due diligence analyses for venture capital, private equity, and large institutional investments, debt instruments, and M&A. Kurt also has a unique practice forming and managing corporate structures using transfer of IP ownership and licensing for tax and operational advantages, and organizing cooperative entities among academic and industry groups to protect and maximize the value of IP rights.
He received his Juris Doctor degree in 1990, and from 1989-1990 was a Scholarship Recipient Editor in Chief of the Loyola of Los Angeles Law Review. He conceived and implemented with winning trade secret defense, patent procurement, and integrated enforcement strategies in the seminal litigation over the fundamental platform for therapeutic fully human antibodies from transgenic mica. “The Mice that Warred,” Scientific American, 2001Jun;284(6):34-5; “Mice with a Human Touch,” Nat Biotechnol. 2007;25(10):1075–1077; 2001 Chemistry & Biology (Cell Press)”Eek, a XenoMouse: Abgenix, Inc.; ” William A. Wells Sept. 2000 New Scientist “No end in sight in the ‘human’ mouse war.”
More recently, Kurt has written his own grant submissions in collaboration with prominent academic and industry scientists for: pharmaceutical intervention in the NLRP3 inflammasome in COVID19, progressive insulin resistance by altering pharmcokinetics in insulin receptor turnover, and pyruvate-based treatment for congestive heart failure.
